Provectus Pharmaceuticals is focused on developing oncology and dermatology therapies. The company’s novel oncology drug, PV-10, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. PVCT’s oncology focus is on melanoma, breast cancer and cancers of the liver. The company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. For more information visit the company’s Web site at www.pvct.com
Let us hear your thoughts below: